summary: In 2006, the results of a six-month clinical trial with oral fingolimod for people with relapsing-remitting MS were published. This treatment proved to be effective in reducing the relapse rate and the MRI inflammatory activity compared with placebo. The authors of this article report the results of the 36-month interim analysis of the extension of the clinical trial, where all participants have been on treatment with fingolimod either since the beginning of the trial or since the seventh month. They found that fingolimod was generally well tolerated by most of the patients, and that the low MRI and clinical disease activity observed at six months were maintained at 36 months.

authors: Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L.

source: Mult Scler. 2009 Dec 22

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: